Clinical Trial Update: Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TheraSphere in combination with systemic therapy for high-risk hepatocellular carcinoma is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Northwestern University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: SUSPENDED